Antidepressant use in pregnant women linked to small increase in autism

A new study found that antidepressant medications taken during pregnancy may be linked to the development of autism in children - although the effect appears to be limited. In looking at a cohort of children born between 2001 and 2011 in Stockholm, Sweden, Drexel University's Brian Lee, PhD, and Craig Newschaffer, PhD, and their co-authors (including lead author Dheeraj Rai, PhD, of the University of Bristol) found that children born to mothers who had taken anti-depressants at any point during their pregnancy were 45 percent more likely to be diagnosed with autism. However, the team's analysis showed that only 2 percent of autism cases would be prevented if antidepressant use was completely cut off in pregnant women.

"Overall, the increase in risk was quite small," said Lee. "Of children exposed to antidepressants during pregnancy, 4.1 percent had an autism diagnosis. In comparison, children of mothers with a history of a psychiatric disorder but who did not use antidepressants during pregnancy had a 2.9 percent prevalence of autism."

The study was published in The BMJ (formerly The British Medical Journal). It focused on prenatal antidepressant use because these medications can cross through the placenta into where the fetus develops.

Past studies have found associations between antidepressant use during pregnancy and autism in children, but there has been some concern that those links were the results of other factors. As such, this study sought to use various methods to rule out any "confounders."

This included looking into the use of antidepressants by the child's father during pregnancy, comparing the children to their siblings, and comparing children with similar characteristics, among other methods.

None of these seemed to significantly affect the main finding linking diagnoses to antidepressant use.

"The overall effect remained," Rai said. "We were specifically looking for consistency in the various analyses we did and the results appeared to concur."

"We conducted several analyses that seemed to support the validity of the findings," Lee added. "For example, because a parental history of a psychiatric disorder is associated with increased risk of autism, we examined whether the father's use of antidepressants was associated with autism. Because there was no increased risk with fathers' use of antidepressants, this suggested that the increase with mothers' use was not entirely due to the underlying psychiatric disorder."

The team found that prenatal antidepressant use seemed to only be linked to autism diagnoses in children who didn't also have intellectual disabilities. This form of autism has a greater chance of inheritability, according to past studies. Genetic traits were not exclusively looked at for the study, although looking at siblings helped mitigate that potential factor. To better examine it in future studies, the study team suggested looking at larger pools of siblings.

And while there was a noticeable increase in autism diagnoses in children whose mothers used the antidepressants, the study team emphasized that more than 95 percent of those women had children who were not diagnosed with autism.

"Our advice for pregnant women and clinicians is very clear. They should not base decisions about the use of antidepressants during pregnancy on any one study, especially when the research evidence is conflicting, as in this case where different studies have reached different conclusions," Rai said. "There could be severe risks of stopping the use of antidepressants during pregnancy, both to the mother and the fetus. So the benefits of these medications for mothers who need them should not be forgotten."

The best course of action is to consult a doctor on medication use during pregnancy.

"Balancing benefits and risks of taking medications during pregnancy is a complex and often difficult decision," he explained. "Our advice would be for women to discuss their concerns with their treating clinicians who will be able to help them weigh the pros and the cons."

As a next step, larger studies will help develop a consensus on the role that both antidepressants and depression itself plays into the risk of autism.

"This may be aided by more studies that could help account for confounding and more studies focusing on the autism group without intellectual disability, which seems to be the key category for which the increase in risk is observed," Rai said.

Rai Dheeraj, Lee Brian K, Dalman Christina, Newschaffer Craig, Lewis Glyn, Magnusson Cecilia et al.
Antidepressants during pregnancy and autism in offspring: population based cohort study.
BMJ 2017; 358 :j2811, doi: 10.1136/bmj.j2811.

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...